Inclusion Criteria:

- Patients with CLL (or small lymphocytic lymphoma) or diagnosis of CLL that progresses
to prolymphocytic leukemia (PLL), or T-cell CLL or PLL

- Patients with B-Cell CLL or PLL who has at least one of the following:

- Failed to meet National Cancer Institute (NCI) Working Group criteria for complete or
partial response after therapy with a regimen containing fludarabine (or another
nucleoside analog, e.g. 2-CDA, pentostatin) or experience disease relapse within 12
months after completing therapy with a regimen containing fludarabine (or another
nucleoside analog)

- Failed FCR combination chemotherapy at any time point

- Had de novo of acquired "17p deletion" cytogenetic abnormality; patients should have
received induction chemotherapy but could be transplanted in 1st complete response
(CR)

- Patient has a suitable human leukocyte antigen (HLA)-matched related donor who is
willing to undergo leukapheresis initially for collection of peripheral blood stem
cells (PBSC) and subsequently for collection of peripheral blood mononuclear cells
(PBMC) with G-CSF mobilization and willing to donate stem cells

- DONOR: Related donor who is HLA phenotypically or genotypically identical at the
allele level at HLA-A, -B, -C, -DRB1, and -DQB1

- DONOR: Donor must consent to G-CSF administration and leukapheresis

- DONOR: Donor must have adequate veins for leukapheresis or agree to placement of
central venous catheter (femoral, subclavian)

Exclusion Criteria:

- Infection with human immunodeficiency virus (HIV), human T-lymphotropic virus
(HTLV)-1, or HTLV-2

- Active central nervous system (CNS) involvement with CLL

- Patients with active non-hematologic malignancies (except non-melanoma skin cancers)

- Patients with a history of non-hematologic malignancies (except non-melanoma skin
cancers) currently in a complete remission, who are less than 5 years from the time
of complete remission, and have a > 20% risk of disease recurrence

- Fertile men or women unwilling to use contraceptive techniques during and for 12
months following treatment

- Pregnant or breastfeeding women

- Karnofsky score =< 70

- Fungal infections with radiological progression after receipt of amphotericin B or
active triazole for greater than 1 month

- Cytotoxic agents for "cytoreduction" (with the exception of Gleevac, cytokine
therapy, hydroxyurea, chlorambucil or rituxan) within three weeks of the initiation
of conditioning

- Active bacterial or fungal infections unresponsive to medical therapy

- Cardiovascular: cardiac ejection fraction < 40%; patients with poorly controlled
hypertension despite multiple antihypertensives

- Pulmonary: diffusing capacity of carbon monoxide (DLCO) < 40%, total lung capacity
(TLC) <40%, forced expiratory volume in one second (FEV1) < 40% and/or requiring
continuous supplementary oxygen, or severe deficits in pulmonary function testing as
defined by pulmonary consultant service

- Liver function abnormalities: patients with clinical or laboratory evidence of liver
disease would be evaluated for the cause of liver disease, its clinical severity in
terms of liver function, bridging fibrosis, and the degree of portal hypertension;
patients will be excluded if they are found to have fulminant liver failure,
cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis,
esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy,
uncorrectable hepatic synthetic dysfunction evinced by prolongation of the
prothrombin time, ascites related to portal hypertension, bacterial or fungal liver
abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin >
3mg/dL, or symptomatic biliary disease

- DONOR: Age < 12 years

- DONOR: Identical twin

- DONOR: Pregnancy

- DONOR: Infection with HIV

- DONOR: Inability to achieve adequate venous access

- DONOR: Known allergy to filgrastin (G-CSF)

- DONOR: Current serious systemic illness